Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH3120 Alone and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT06234397Phase 1Recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of BH3120 in solid tumor (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Adverse Events and Laboratory Abnormalities and Dose-Limiting Toxicities at 21 days. Started Dec 2023; status: recruiting.
02
Drugs
BH3120
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06234397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234397.